A77 1726 cas 163451-81-8
Teriflunomide is an immunomodulator with anti-inflammatory properties used to treat patients with the rare disease multiple sclerosis.
163451-81-8
C12H9F3N2O2
270.21
642-273-4
A771726(Teriflunomide);a1726;flucyamide;hmr1726;(Z)-2-Cyano-3-Hydroxy-N-[4-(Trifluoromethyl)phenyl]-2-Chemicalbookbutenamide;leflunomideepimpurityb;leflunomideimpurity2(Leflunomideepimpurityb);a- 771726;a771726;a771726
Melting Point | 229-232°C |
Boiling Point | 410.8±45.0 °C(Predicted) |
Density | 1.424±0.06 g/cm3(Predicted) |
Storage conditions | -20°C |
Solubility | DMSO: soluble 5mg/mL, clear (heated) |
Acidity coefficient (pKa) | 5.20±0.50(Predicted) |
Form | powder |
Color | white to beige |
Maximum wavelength (λmax) | 203nm(MeOH)(lit.) |
Merck | 14,9165 |
Stability | Hygroscopicity |
InChIKey | UTNUDOFZCWSZMS-YFHOEESVSA-N |
The multiple sclerosis drug teriflunomide is an immunomodulator with anti-inflammatory properties used to treat patients with the rare disease multiple sclerosis. In 2018, multiple sclerosis was included in the first list of rare diseases released by my country. In the same year, teriflunomide officially entered my country as the first oral disease-modifying treatment drug.
Teriflunomide is an immunomodulator with anti-inflammatory effects that inhibits dihydroorotate dehydrogenase involved in de novo pyrimidine synthesis.
Headache, hair loss, diarrhea, nausea, and skin reactions may occur after taking teriflunomide. Before taking teriflunomide, blood routine, liver function, blood pressure, and tuberculosis screening should be monitored; liver function should be monitored monthly for the first 6 months and every 6 months thereafter.